APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Oligonucleotide CDMO

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Oligonucleotide CDMO Market Analysis and Forecast 2026-2032

Report ID 174201460215 April 2026214 pages

Choose your research edition.

Industry ResearchOligonucleotide CDMO Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Oligonucleotide CDMO Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Oligonucleotide CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oligonucleotide CDMO Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Oligonucleotide CDMO Market Analysis and Forecast 2026-2032214 pages · $4,950 USD

Market perspective

The global Oligonucleotide CDMO market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Oligonucleotide CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Oligonucleotide CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Oligonucleotide CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Oligonucleotide CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Oligonucleotide CDMO include Agilent, ST Pharm, Bachem, BioSpring, Creative Biogene, Sylentis, Ajinomoto Bio-Pharma, EUROAPI and Veliter, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Oligonucleotide CDMO, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Oligonucleotide CDMO, also provides the revenue of main regions and countries. Of the upcoming market potential for Oligonucleotide CDMO, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Oligonucleotide CDMO revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Oligonucleotide CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Oligonucleotide CDMO revenue, projected growth trends, production technology, application and end-user industry.

Oligonucleotide CDMO Segment by Company

Agilent

ST Pharm

Bachem

BioSpring

Creative Biogene

Sylentis

Ajinomoto Bio-Pharma

EUROAPI

Veliter

PolyPeptide Group

CordenPharma

Thermofischer

Bio Basic

Genscript

Cytiva

ScinoPharm

CBL

Piramal Pharma

CPC Scientific

Eurogentec

Cambrex

WuXi STA

Oligonucleotide CDMO Segment by Type

APIs and Intermediates

FDF

Oligonucleotide CDMO Segment by Application

Pharmaceutical and Biotechnology Companies

Research Institutes

Others

Oligonucleotide CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oligonucleotide CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oligonucleotide CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oligonucleotide CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Oligonucleotide CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Oligonucleotide CDMO company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oligonucleotide CDMO revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Oligonucleotide CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. APIs and Intermediates Major Player Table 3. FDF Major Player Table 4. Global Oligonucleotide CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Pharmaceutical and Biotechnology Companies Major Player Table 6. Research Institutes Major Player Table 7. Others Major Player Table 8. Oligonucleotide CDMO Industry Trends Table 9. Oligonucleotide CDMO Industry Drivers Table 10. Oligonucleotide CDMO Industry Opportunities and Challenges Table 11. Oligonucleotide CDMO Industry Restraints Table 12. Global Oligonucleotide CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Oligonucleotide CDMO Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Oligonucleotide CDMO Market Share by Region (2021-2026) Table 15. Global Oligonucleotide CDMO Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Oligonucleotide CDMO Market Share by Region (2027-2032) Table 17. Global Oligonucleotide CDMO Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Oligonucleotide CDMO Revenue Market Share by Players (2021-2026) Table 19. Global Oligonucleotide CDMO Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Oligonucleotide CDMO Key Players Headquarters & Area Served Table 21. Global Oligonucleotide CDMO Players, Product Type & Application Table 22. Global Oligonucleotide CDMO Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Oligonucleotide CDMO by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Oligonucleotide CDMO Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Oligonucleotide CDMO Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Oligonucleotide CDMO Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Oligonucleotide CDMO Revenue Market Share by Type (2021-2026) Table 29. Global Oligonucleotide CDMO Revenue Market Share by Type (2027-2032) Table 30. Global Oligonucleotide CDMO Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Oligonucleotide CDMO Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Oligonucleotide CDMO Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Oligonucleotide CDMO Revenue Market Share by Application (2021-2026) Table 34. Global Oligonucleotide CDMO Revenue Market Share by Application (2027-2032) Table 35. Agilent Company Information Table 36. Agilent Business Overview Table 37. Agilent Oligonucleotide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Agilent Oligonucleotide CDMO Product Portfolio Table 39. Agilent Recent Development Table 40. ST Pharm Company Information Table 41. ST Pharm Business Overview Table 42. ST Pharm Oligonucleotide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. ST Pharm Oligonucleotide CDMO Product Portfolio Table 44. ST Pharm Recent Development Table 45. Bachem Company Information Table 46. Bachem Business Overview Table 47. Bachem Oligonucleotide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Bachem Oligonucleotide CDMO Product Portfolio Table 49. Bachem Recent Development Table 50. BioSpring Company Information Table 51. BioSpring Business Overview Table 52. BioSpring Oligonucleotide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. BioSpring Oligonucleotide CDMO Product Portfolio Table 54. BioSpring Recent Development Table 55. Creative Biogene Company Information Table 56. Creative Biogene Business Overview Table 57. Creative Biogene Oligonucleotide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Creative Biogene Oligonucleotide CDMO Product Portfolio Table 59. Creative Biogene Recent Development Table 60. Sylentis Company Information Table 61. Sylentis Business Overview Table 62. Sylentis Oligonucleotide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Sylentis Oligonucleotide CDMO Product Portfolio Table 64. Sylentis Recent Development Table 65. Ajinomoto Bio-Pharma Company Information Table 66. Ajinomoto Bio-Pharma Business Overview Table 67. Ajinomoto Bio-Pharma Oligonucleotide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Ajinomoto Bio-Pharma Oligonucleotide CDMO Product Portfolio Table 69. Ajinomoto Bio-Pharma Recent Development Table 70. EUROAPI Company Information Table 71. EUROAPI Business Overview Table 72. EUROAPI Oligonucleotide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. EUROAPI Oligonucleotide CDMO Product Portfolio Table 74. EUROAPI Recent Development Table 75. Veliter Company Information Table 76. Veliter Business Overview Table 77. Veliter Oligonucleotide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Veliter Oligonucleotide CDMO Product Portfolio Table 79. Veliter Recent Development Table 80. PolyPeptide Group Company Information Table 81. PolyPeptide Group Business Overview Table 82. PolyPeptide Group Oligonucleotide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. PolyPeptide Group Oligonucleotide CDMO Product Portfolio Table 84. PolyPeptide Group Recent Development Table 85. CordenPharma Company Information Table 86. CordenPharma Business Overview Table 87. CordenPharma Oligonucleotide CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 88. CordenPharma Oligonucleotide CDMO Product Portfolio Table 89. CordenPharma Recent Development Table 90. Thermofischer Company Information Table 91. Thermofischer Business Overview Table 92. Thermofischer Oligonucleotide CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Thermofischer Oligonucleotide CDMO Product Portfolio Table 94. Thermofischer Recent Development Table 95. Bio Basic Company Information Table 96. Bio Basic Business Overview Table 97. Bio Basic Oligonucleotide CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Bio Basic Oligonucleotide CDMO Product Portfolio Table 99. Bio Basic Recent Development Table 100. Genscript Company Information Table 101. Genscript Business Overview Table 102. Genscript Oligonucleotide CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. Genscript Oligonucleotide CDMO Product Portfolio Table 104. Genscript Recent Development Table 105. Cytiva Company Information Table 106. Cytiva Business Overview Table 107. Cytiva Oligonucleotide CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. Cytiva Oligonucleotide CDMO Product Portfolio Table 109. Cytiva Recent Development Table 110. ScinoPharm Company Information Table 111. ScinoPharm Business Overview Table 112. ScinoPharm Oligonucleotide CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 113. ScinoPharm Oligonucleotide CDMO Product Portfolio Table 114. ScinoPharm Recent Development Table 115. CBL Company Information Table 116. CBL Business Overview Table 117. CBL Oligonucleotide CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 118. CBL Oligonucleotide CDMO Product Portfolio Table 119. CBL Recent Development Table 120. Piramal Pharma Company Information Table 121. Piramal Pharma Business Overview Table 122. Piramal Pharma Oligonucleotide CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 123. Piramal Pharma Oligonucleotide CDMO Product Portfolio Table 124. Piramal Pharma Recent Development Table 125. CPC Scientific Company Information Table 126. CPC Scientific Business Overview Table 127. CPC Scientific Oligonucleotide CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 128. CPC Scientific Oligonucleotide CDMO Product Portfolio Table 129. CPC Scientific Recent Development Table 130. Eurogentec Company Information Table 131. Eurogentec Business Overview Table 132. Eurogentec Oligonucleotide CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 133. Eurogentec Oligonucleotide CDMO Product Portfolio Table 134. Eurogentec Recent Development Table 135. Cambrex Company Information Table 136. Cambrex Business Overview Table 137. Cambrex Oligonucleotide CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 138. Cambrex Oligonucleotide CDMO Product Portfolio Table 139. Cambrex Recent Development Table 140. WuXi STA Company Information Table 141. WuXi STA Business Overview Table 142. WuXi STA Oligonucleotide CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 143. WuXi STA Oligonucleotide CDMO Product Portfolio Table 144. WuXi STA Recent Development Table 145. North America Oligonucleotide CDMO Revenue by Type (2021-2026) & (US$ Million) Table 146. North America Oligonucleotide CDMO Revenue by Type (2027-2032) & (US$ Million) Table 147. North America Oligonucleotide CDMO Revenue by Application (2021-2026) & (US$ Million) Table 148. North America Oligonucleotide CDMO Revenue by Application (2027-2032) & (US$ Million) Table 149. North America Oligonucleotide CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 150. North America Oligonucleotide CDMO Revenue by Country (2021-2026) & (US$ Million) Table 151. North America Oligonucleotide CDMO Revenue by Country (US$ Million) & (2027-2032) Table 152. Europe Oligonucleotide CDMO Revenue by Type (2021-2026) & (US$ Million) Table 153. Europe Oligonucleotide CDMO Revenue by Type (2027-2032) & (US$ Million) Table 154. Europe Oligonucleotide CDMO Revenue by Application (2021-2026) & (US$ Million) Table 155. Europe Oligonucleotide CDMO Revenue by Application (2027-2032) & (US$ Million) Table 156. Europe Oligonucleotide CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 157. Europe Oligonucleotide CDMO Revenue by Country (2021-2026) & (US$ Million) Table 158. Europe Oligonucleotide CDMO Revenue by Country (US$ Million) & (2027-2032) Table 159. China Oligonucleotide CDMO Revenue by Type (2021-2026) & (US$ Million) Table 160. China Oligonucleotide CDMO Revenue by Type (2027-2032) & (US$ Million) Table 161. China Oligonucleotide CDMO Revenue by Application (2021-2026) & (US$ Million) Table 162. China Oligonucleotide CDMO Revenue by Application (2027-2032) & (US$ Million) Table 163. Asia Oligonucleotide CDMO Revenue by Type (2021-2026) & (US$ Million) Table 164. Asia Oligonucleotide CDMO Revenue by Type (2027-2032) & (US$ Million) Table 165. Asia Oligonucleotide CDMO Revenue by Application (2021-2026) & (US$ Million) Table 166. Asia Oligonucleotide CDMO Revenue by Application (2027-2032) & (US$ Million) Table 167. Asia Oligonucleotide CDMO Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 168. Asia Oligonucleotide CDMO Revenue by Region (US$ Million) & (2021-2026) Table 169. Asia Oligonucleotide CDMO Revenue by Region (US$ Million) & (2027-2032) Table 170. SAMEA Oligonucleotide CDMO Revenue by Type (2021-2026) & (US$ Million) Table 171. SAMEA Oligonucleotide CDMO Revenue by Type (2027-2032) & (US$ Million) Table 172. SAMEA Oligonucleotide CDMO Revenue by Application (2021-2026) & (US$ Million) Table 173. SAMEA Oligonucleotide CDMO Revenue by Application (2027-2032) & (US$ Million) Table 174. SAMEA Oligonucleotide CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 175. SAMEA Oligonucleotide CDMO Revenue by Country (2021-2026) & (US$ Million) Table 176. SAMEA Oligonucleotide CDMO Revenue by Country (US$ Million) & (2027-2032) Table 177. Research Programs/Design for This Report Table 178. Authors List of This Report Table 179. Secondary Sources Table 180. Primary Sources List of Figures Figure 1. Oligonucleotide CDMO Image Figure 2. Global Oligonucleotide CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oligonucleotide CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 4. APIs and Intermediates Image Figure 5. FDF Image Figure 6. Global Oligonucleotide CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Oligonucleotide CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 8. Pharmaceutical and Biotechnology Companies Image Figure 9. Research Institutes Image Figure 10. Others Image Figure 11. Global Oligonucleotide CDMO Market Size (US$ Million) & (2021-2032) Figure 12. Global Oligonucleotide CDMO Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Oligonucleotide CDMO Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Oligonucleotide CDMO Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Oligonucleotide CDMO Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Oligonucleotide CDMO Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Oligonucleotide CDMO Revenue Market Share by Type (2021-2032) Figure 19. Global Oligonucleotide CDMO Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Oligonucleotide CDMO Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Oligonucleotide CDMO Revenue Market Share by Application (2021-2032) Figure 22. North America Oligonucleotide CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Oligonucleotide CDMO Revenue Share by Type (2021-2032) Figure 24. North America Oligonucleotide CDMO Revenue Share by Application (2021-2032) Figure 25. North America Oligonucleotide CDMO Revenue Share by Country (2021-2032) Figure 26. United States Oligonucleotide CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Oligonucleotide CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Oligonucleotide CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Oligonucleotide CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Oligonucleotide CDMO Revenue Share by Type (2021-2032) Figure 31. Europe Oligonucleotide CDMO Revenue Share by Application (2021-2032) Figure 32. Europe Oligonucleotide CDMO Revenue Share by Country (2021-2032) Figure 33. Germany Oligonucleotide CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Oligonucleotide CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Oligonucleotide CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Oligonucleotide CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Oligonucleotide CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Oligonucleotide CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Oligonucleotide CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Oligonucleotide CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Oligonucleotide CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Oligonucleotide CDMO Revenue Share by Type (2021-2032) Figure 43. China Oligonucleotide CDMO Revenue Share by Application (2021-2032) Figure 44. Asia Oligonucleotide CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Oligonucleotide CDMO Revenue Share by Type (2021-2032) Figure 46. Asia Oligonucleotide CDMO Revenue Share by Application (2021-2032) Figure 47. Asia Oligonucleotide CDMO Revenue Share by Region (2021-2032) Figure 48. Japan Oligonucleotide CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Oligonucleotide CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Oligonucleotide CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Oligonucleotide CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Oligonucleotide CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Oligonucleotide CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Oligonucleotide CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Oligonucleotide CDMO Revenue Share by Type (2021-2032) Figure 56. SAMEA Oligonucleotide CDMO Revenue Share by Application (2021-2032) Figure 57. SAMEA Oligonucleotide CDMO Revenue Share by Country (2021-2032) Figure 58. Brazil Oligonucleotide CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Oligonucleotide CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Oligonucleotide CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Oligonucleotide CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Oligonucleotide CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Oligonucleotide CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Oligonucleotide CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Oligonucleotide CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Oligonucleotide CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Oligonucleotide CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Oligonucleotide CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • APIs and Intermediates
  • FDF
Applications
  • Pharmaceutical and Biotechnology Companies
  • Research Institutes
  • Others
Companies covered
  • Agilent
  • ST Pharm
  • Bachem
  • BioSpring
  • Creative Biogene
  • Sylentis
  • Ajinomoto Bio-Pharma
  • EUROAPI
  • Veliter
  • PolyPeptide Group
  • CordenPharma
  • Thermofischer
  • Bio Basic
  • Genscript
  • Cytiva
  • ScinoPharm
  • CBL
  • Piramal Pharma
  • CPC Scientific
  • Eurogentec
  • Cambrex
  • WuXi STA

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Oligonucleotide CDMO Market by Type
  3. 1.2.1 Global Oligonucleotide CDMO Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 APIs and Intermediates
  5. 1.2.3 FDF
  6. 1.3 Oligonucleotide CDMO Market by Application
  7. 1.3.1 Global Oligonucleotide CDMO Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Pharmaceutical and Biotechnology Companies
  9. 1.3.3 Research Institutes
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Oligonucleotide CDMO Market Dynamics
  1. 2.1 Oligonucleotide CDMO Industry Trends
  2. 2.2 Oligonucleotide CDMO Industry Drivers
  3. 2.3 Oligonucleotide CDMO Industry Opportunities and Challenges
  4. 2.4 Oligonucleotide CDMO Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Oligonucleotide CDMO Market Perspective (2021-2032)
  2. 3.2 Global Oligonucleotide CDMO Growth Trends by Region
  3. 3.2.1 Global Oligonucleotide CDMO Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Oligonucleotide CDMO Market Size by Region (2021-2026)
  5. 3.2.3 Global Oligonucleotide CDMO Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Oligonucleotide CDMO Revenue by Players
  2. 4.1.1 Global Oligonucleotide CDMO Revenue by Players (2021-2026)
  3. 4.1.2 Global Oligonucleotide CDMO Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Oligonucleotide CDMO Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Oligonucleotide CDMO Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Oligonucleotide CDMO Key Players Headquarters & Area Served
  7. 4.4 Global Oligonucleotide CDMO Players, Product Type & Application
  8. 4.5 Global Oligonucleotide CDMO Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Oligonucleotide CDMO Market CR5 and HHI
  11. 4.6.3 2025 Oligonucleotide CDMO Tier 1, Tier 2, and Tier 3
5 Oligonucleotide CDMO Market Size by Type
  1. 5.1 Global Oligonucleotide CDMO Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Oligonucleotide CDMO Revenue by Type (2021-2032)
  3. 5.3 Global Oligonucleotide CDMO Revenue Market Share by Type (2021-2032)
6 Oligonucleotide CDMO Market Size by Application
  1. 6.1 Global Oligonucleotide CDMO Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Oligonucleotide CDMO Revenue by Application (2021-2032)
  3. 6.3 Global Oligonucleotide CDMO Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Agilent
  2. 7.1.1 Agilent Company Information
  3. 7.1.2 Agilent Business Overview
  4. 7.1.3 Agilent Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Agilent Oligonucleotide CDMO Product Portfolio
  6. 7.1.5 Agilent Recent Developments
  7. 7.2 ST Pharm
  8. 7.2.1 ST Pharm Company Information
  9. 7.2.2 ST Pharm Business Overview
  10. 7.2.3 ST Pharm Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  11. 7.2.4 ST Pharm Oligonucleotide CDMO Product Portfolio
  12. 7.2.5 ST Pharm Recent Developments
  13. 7.3 Bachem
  14. 7.3.1 Bachem Company Information
  15. 7.3.2 Bachem Business Overview
  16. 7.3.3 Bachem Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Bachem Oligonucleotide CDMO Product Portfolio
  18. 7.3.5 Bachem Recent Developments
  19. 7.4 BioSpring
  20. 7.4.1 BioSpring Company Information
  21. 7.4.2 BioSpring Business Overview
  22. 7.4.3 BioSpring Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  23. 7.4.4 BioSpring Oligonucleotide CDMO Product Portfolio
  24. 7.4.5 BioSpring Recent Developments
  25. 7.5 Creative Biogene
  26. 7.5.1 Creative Biogene Company Information
  27. 7.5.2 Creative Biogene Business Overview
  28. 7.5.3 Creative Biogene Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Creative Biogene Oligonucleotide CDMO Product Portfolio
  30. 7.5.5 Creative Biogene Recent Developments
  31. 7.6 Sylentis
  32. 7.6.1 Sylentis Company Information
  33. 7.6.2 Sylentis Business Overview
  34. 7.6.3 Sylentis Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Sylentis Oligonucleotide CDMO Product Portfolio
  36. 7.6.5 Sylentis Recent Developments
  37. 7.7 Ajinomoto Bio-Pharma
  38. 7.7.1 Ajinomoto Bio-Pharma Company Information
  39. 7.7.2 Ajinomoto Bio-Pharma Business Overview
  40. 7.7.3 Ajinomoto Bio-Pharma Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Ajinomoto Bio-Pharma Oligonucleotide CDMO Product Portfolio
  42. 7.7.5 Ajinomoto Bio-Pharma Recent Developments
  43. 7.8 EUROAPI
  44. 7.8.1 EUROAPI Company Information
  45. 7.8.2 EUROAPI Business Overview
  46. 7.8.3 EUROAPI Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  47. 7.8.4 EUROAPI Oligonucleotide CDMO Product Portfolio
  48. 7.8.5 EUROAPI Recent Developments
  49. 7.9 Veliter
  50. 7.9.1 Veliter Company Information
  51. 7.9.2 Veliter Business Overview
  52. 7.9.3 Veliter Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Veliter Oligonucleotide CDMO Product Portfolio
  54. 7.9.5 Veliter Recent Developments
  55. 7.10 PolyPeptide Group
  56. 7.10.1 PolyPeptide Group Company Information
  57. 7.10.2 PolyPeptide Group Business Overview
  58. 7.10.3 PolyPeptide Group Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  59. 7.10.4 PolyPeptide Group Oligonucleotide CDMO Product Portfolio
  60. 7.10.5 PolyPeptide Group Recent Developments
  61. 7.11 CordenPharma
  62. 7.11.1 CordenPharma Company Information
  63. 7.11.2 CordenPharma Business Overview
  64. 7.11.3 CordenPharma Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  65. 7.11.4 CordenPharma Oligonucleotide CDMO Product Portfolio
  66. 7.11.5 CordenPharma Recent Developments
  67. 7.12 Thermofischer
  68. 7.12.1 Thermofischer Company Information
  69. 7.12.2 Thermofischer Business Overview
  70. 7.12.3 Thermofischer Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Thermofischer Oligonucleotide CDMO Product Portfolio
  72. 7.12.5 Thermofischer Recent Developments
  73. 7.13 Bio Basic
  74. 7.13.1 Bio Basic Company Information
  75. 7.13.2 Bio Basic Business Overview
  76. 7.13.3 Bio Basic Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Bio Basic Oligonucleotide CDMO Product Portfolio
  78. 7.13.5 Bio Basic Recent Developments
  79. 7.14 Genscript
  80. 7.14.1 Genscript Company Information
  81. 7.14.2 Genscript Business Overview
  82. 7.14.3 Genscript Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Genscript Oligonucleotide CDMO Product Portfolio
  84. 7.14.5 Genscript Recent Developments
  85. 7.15 Cytiva
  86. 7.15.1 Cytiva Company Information
  87. 7.15.2 Cytiva Business Overview
  88. 7.15.3 Cytiva Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Cytiva Oligonucleotide CDMO Product Portfolio
  90. 7.15.5 Cytiva Recent Developments
  91. 7.16 ScinoPharm
  92. 7.16.1 ScinoPharm Company Information
  93. 7.16.2 ScinoPharm Business Overview
  94. 7.16.3 ScinoPharm Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  95. 7.16.4 ScinoPharm Oligonucleotide CDMO Product Portfolio
  96. 7.16.5 ScinoPharm Recent Developments
  97. 7.17 CBL
  98. 7.17.1 CBL Company Information
  99. 7.17.2 CBL Business Overview
  100. 7.17.3 CBL Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  101. 7.17.4 CBL Oligonucleotide CDMO Product Portfolio
  102. 7.17.5 CBL Recent Developments
  103. 7.18 Piramal Pharma
  104. 7.18.1 Piramal Pharma Company Information
  105. 7.18.2 Piramal Pharma Business Overview
  106. 7.18.3 Piramal Pharma Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Piramal Pharma Oligonucleotide CDMO Product Portfolio
  108. 7.18.5 Piramal Pharma Recent Developments
  109. 7.19 CPC Scientific
  110. 7.19.1 CPC Scientific Company Information
  111. 7.19.2 CPC Scientific Business Overview
  112. 7.19.3 CPC Scientific Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  113. 7.19.4 CPC Scientific Oligonucleotide CDMO Product Portfolio
  114. 7.19.5 CPC Scientific Recent Developments
  115. 7.20 Eurogentec
  116. 7.20.1 Eurogentec Company Information
  117. 7.20.2 Eurogentec Business Overview
  118. 7.20.3 Eurogentec Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Eurogentec Oligonucleotide CDMO Product Portfolio
  120. 7.20.5 Eurogentec Recent Developments
  121. 7.21 Cambrex
  122. 7.21.1 Cambrex Company Information
  123. 7.21.2 Cambrex Business Overview
  124. 7.21.3 Cambrex Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  125. 7.21.4 Cambrex Oligonucleotide CDMO Product Portfolio
  126. 7.21.5 Cambrex Recent Developments
  127. 7.22 WuXi STA
  128. 7.22.1 WuXi STA Company Information
  129. 7.22.2 WuXi STA Business Overview
  130. 7.22.3 WuXi STA Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  131. 7.22.4 WuXi STA Oligonucleotide CDMO Product Portfolio
  132. 7.22.5 WuXi STA Recent Developments
8 North America
  1. 8.1 North America Oligonucleotide CDMO Revenue (2021-2032)
  2. 8.2 North America Oligonucleotide CDMO Revenue by Type (2021-2032)
  3. 8.2.1 North America Oligonucleotide CDMO Revenue by Type (2021-2026)
  4. 8.2.2 North America Oligonucleotide CDMO Revenue by Type (2027-2032)
  5. 8.3 North America Oligonucleotide CDMO Revenue Share by Type (2021-2032)
  6. 8.4 North America Oligonucleotide CDMO Revenue by Application (2021-2032)
  7. 8.4.1 North America Oligonucleotide CDMO Revenue by Application (2021-2026)
  8. 8.4.2 North America Oligonucleotide CDMO Revenue by Application (2027-2032)
  9. 8.5 North America Oligonucleotide CDMO Revenue Share by Application (2021-2032)
  10. 8.6 North America Oligonucleotide CDMO Revenue by Country
  11. 8.6.1 North America Oligonucleotide CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Oligonucleotide CDMO Revenue by Country (2021-2026)
  13. 8.6.3 North America Oligonucleotide CDMO Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Oligonucleotide CDMO Revenue (2021-2032)
  2. 9.2 Europe Oligonucleotide CDMO Revenue by Type (2021-2032)
  3. 9.2.1 Europe Oligonucleotide CDMO Revenue by Type (2021-2026)
  4. 9.2.2 Europe Oligonucleotide CDMO Revenue by Type (2027-2032)
  5. 9.3 Europe Oligonucleotide CDMO Revenue Share by Type (2021-2032)
  6. 9.4 Europe Oligonucleotide CDMO Revenue by Application (2021-2032)
  7. 9.4.1 Europe Oligonucleotide CDMO Revenue by Application (2021-2026)
  8. 9.4.2 Europe Oligonucleotide CDMO Revenue by Application (2027-2032)
  9. 9.5 Europe Oligonucleotide CDMO Revenue Share by Application (2021-2032)
  10. 9.6 Europe Oligonucleotide CDMO Revenue by Country
  11. 9.6.1 Europe Oligonucleotide CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Oligonucleotide CDMO Revenue by Country (2021-2026)
  13. 9.6.3 Europe Oligonucleotide CDMO Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Oligonucleotide CDMO Revenue (2021-2032)
  2. 10.2 China Oligonucleotide CDMO Revenue by Type (2021-2032)
  3. 10.2.1 China Oligonucleotide CDMO Revenue by Type (2021-2026)
  4. 10.2.2 China Oligonucleotide CDMO Revenue by Type (2027-2032)
  5. 10.3 China Oligonucleotide CDMO Revenue Share by Type (2021-2032)
  6. 10.4 China Oligonucleotide CDMO Revenue by Application (2021-2032)
  7. 10.4.1 China Oligonucleotide CDMO Revenue by Application (2021-2026)
  8. 10.4.2 China Oligonucleotide CDMO Revenue by Application (2027-2032)
  9. 10.5 China Oligonucleotide CDMO Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Oligonucleotide CDMO Revenue (2021-2032)
  2. 11.2 Asia Oligonucleotide CDMO Revenue by Type (2021-2032)
  3. 11.2.1 Asia Oligonucleotide CDMO Revenue by Type (2021-2026)
  4. 11.2.2 Asia Oligonucleotide CDMO Revenue by Type (2027-2032)
  5. 11.3 Asia Oligonucleotide CDMO Revenue Share by Type (2021-2032)
  6. 11.4 Asia Oligonucleotide CDMO Revenue by Application (2021-2032)
  7. 11.4.1 Asia Oligonucleotide CDMO Revenue by Application (2021-2026)
  8. 11.4.2 Asia Oligonucleotide CDMO Revenue by Application (2027-2032)
  9. 11.5 Asia Oligonucleotide CDMO Revenue Share by Application (2021-2032)
  10. 11.6 Asia Oligonucleotide CDMO Revenue by Country
  11. 11.6.1 Asia Oligonucleotide CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Oligonucleotide CDMO Revenue by Country (2021-2026)
  13. 11.6.3 Asia Oligonucleotide CDMO Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Oligonucleotide CDMO Revenue (2021-2032)
  2. 12.2 SAMEA Oligonucleotide CDMO Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Oligonucleotide CDMO Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Oligonucleotide CDMO Revenue by Type (2027-2032)
  5. 12.3 SAMEA Oligonucleotide CDMO Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Oligonucleotide CDMO Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Oligonucleotide CDMO Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Oligonucleotide CDMO Revenue by Application (2027-2032)
  9. 12.5 SAMEA Oligonucleotide CDMO Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Oligonucleotide CDMO Revenue by Country
  11. 12.6.1 SAMEA Oligonucleotide CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Oligonucleotide CDMO Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Oligonucleotide CDMO Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst